Chapter 1: Executive Summary
Emerging Infectious Diseases
Technologies
Products and Applications
Drug-Resistant Pathogens
Technologies
Products and Applications
Food and Waterborne Infectious Diseases
Technologies
Products and Applications
Biodefense
Technologies
Products and Applications
Market Analysis
Market Dynamics and Trends
Chapter 2: Introduction
Scope and Objectives of the Report
References
Chapter 3: Emerging Infectious Diseases
Introduction
West Nile Virus
SARS
Influenza
Mad Cow Disease
Technologies
Products and Applications
Diagnostic Products and Applications
Therapeutic Products and Applications
Deals, Grants, and Contracts
References
Chapter 4: Drug-Resistant Pathogens
Technologies
Products and Applications
Deals, Grants, and Contracts
References
Chapter 5: Food and Waterborne Infectious Diseases
Technologies
Products and Applications
References
Chapter 6: Biodefense
Technologies
Products and Applications
Deals, Grants, and Contracts
References
Chapter 7: Markets
Market Analysis
Market Dynamics and Trends
References
Chapter 8: Company Profiles
Acambis plc
AVANT Immunotherapeutics, Inc
Bio-Rad Laboratories
Cepheid
Coley Pharmaceutical Group, Inc
Cubist Pharmaceuticals, Inc.
DuPont Qualicon
DynPort Vaccine Company LLC
Hemispherx Biopharma, Inc.
Infectio Diagnostic Inc.
IGEN International, Inc
Inhibitex, Inc
Meridian Bioscience, Inc.
MicroFluidic Systems, Inc
Neogen Corporation
New Horizons Diagnostics, Inc.
Prionics AG
Q-RNA, Inc.
Quorex Pharmaceuticals, Inc.
Response Biomedical Corporation
SIGA Technologies, Inc.
Strategic Diagnostics Inc.
Tetracore, Inc.
VaxGen Inc.
Chapter 9: Interviews with Industry Experts
Piers Whitehead, VP of Corporate and Business Development, VaxGen, Inc.
Valerie Ceva, Partner, Homeland Defense Ventures
Abraham Grossman, Ph.D., Founder and CEO, Q-RNA, Inc
Dr. Kenneth Alibek, Executive Director, National Center for Biodefense, Distinguished Professor, George Mason University
